{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:50:08Z","timestamp":1772121008161,"version":"3.50.1"},"publisher-location":"Cham","reference-count":165,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783031358067","type":"print"},{"value":"9783031358074","type":"electronic"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1007\/82_2022_261","type":"book-chapter","created":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T23:03:55Z","timestamp":1666047835000},"page":"111-145","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Lassa Virus Countermeasures"],"prefix":"10.1007","author":[{"given":"Lilia I.","family":"Melnik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,18]]},"reference":[{"issue":"1","key":"261_CR1","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1038\/s41467-018-06741-w","volume":"9","author":"T Abreu-Mota","year":"2018","unstructured":"Abreu-Mota T, Hagen KR, Cooper K, Jahrling PB, Tan G, Wirblich C, Johnson RF, Schnell MJ (2018) Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever. Nat Commun 9(1):4223","journal-title":"Nat Commun"},{"issue":"3","key":"261_CR2","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/nm.2105","volume":"16","author":"W Akahata","year":"2010","unstructured":"Akahata W, Yang ZY, Andersen H, Sun S, Holdaway HA, Kong WP, Lewis MG, Higgs S, Rossmann MG, Rao S, Nabel GJ (2010) A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nat Med 16(3):334\u2013338","journal-title":"Nat Med"},{"key":"261_CR3","doi-asserted-by":"crossref","unstructured":"Amanat F, Duehr J, Huang C, Paessler S, Tan GS, Krammer F (2020) Monoclonal antibodies with neutralizing activity and Fc-effector functions against the machupo virus glycoprotein. J Virol 94(5)","DOI":"10.1128\/JVI.01741-19"},{"issue":"6","key":"261_CR4","doi-asserted-by":"crossref","first-page":"694","DOI":"10.4161\/hv.7.6.15198","volume":"7","author":"A Ambrosio","year":"2011","unstructured":"Ambrosio A, Saavedra M, Mariani M, Gamboa G, Maiza A (2011) Argentine hemorrhagic fever vaccines. Hum Vaccin 7(6):694\u2013700","journal-title":"Hum Vaccin"},{"issue":"2","key":"261_CR5","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000149662","volume":"25","author":"AM Ambrosio","year":"1986","unstructured":"Ambrosio AM, Enria DA, Maiztegui JI (1986) Junin virus isolation from lympho-mononuclear cells of patients with Argentine hemorrhagic fever. Intervirology 25(2):97\u2013102","journal-title":"Intervirology"},{"issue":"1","key":"261_CR6","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0042-6822(86)90438-1","volume":"154","author":"DD Auperin","year":"1986","unstructured":"Auperin DD, Sasso DR, McCormick JB (1986) Nucleotide sequence of the glycoprotein gene and intergenic region of the Lassa virus S genome RNA. Virology 154(1):155\u2013167","journal-title":"Virology"},{"issue":"5","key":"261_CR7","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.4049\/jimmunol.172.5.2861","volume":"172","author":"S Baize","year":"2004","unstructured":"Baize S, Kaplon J, Faure C, Pannetier D, Georges-Courbot MC, Deubel V (2004) Lassa virus infection of human dendritic cells and macrophages is productive but fails to activate cells. J Immunol 172(5):2861\u20132869","journal-title":"J Immunol"},{"issue":"5","key":"261_CR8","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.micinf.2006.02.002","volume":"8","author":"S Baize","year":"2006","unstructured":"Baize S, Pannetier D, Faure C, Marianneau P, Marendat I, Georges-Courbot MC, Deubel V (2006) Role of interferons in the control of Lassa virus replication in human dendritic cells and macrophages. Microbes Infect 8(5):1194\u20131202","journal-title":"Microbes Infect"},{"issue":"7","key":"261_CR9","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1128\/JCM.38.7.2670-2677.2000","volume":"38","author":"DG Bausch","year":"2000","unstructured":"Bausch DG, Rollin PE, Demby AH, Coulibaly M, Kanu J, Conteh AS, Wagoner KD, McMullan LK, Bowen MD, Peters CJ, Ksiazek TG (2000) Diagnosis and clinical virology of Lassa fever as evaluated by enzyme-linked immunosorbent assay, indirect fluorescent-antibody test, and virus isolation. J Clin Microbiol 38(7):2670\u20132677","journal-title":"J Clin Microbiol"},{"key":"261_CR10","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.antiviral.2014.04.006","volume":"107","author":"J Blaising","year":"2014","unstructured":"Blaising J, Polyak SJ, P\u00e9cheur EI (2014) Arbidol as a broad-spectrum antiviral: an update. Antiviral Res 107:84\u201394","journal-title":"Antiviral Res"},{"issue":"2","key":"261_CR11","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/INF.0b013e3181b77906","volume":"29","author":"SL Block","year":"2010","unstructured":"Block SL, Brown DR, Chatterjee A, Gold MA, Sings HL, Meibohm A, Dana A, Haupt RM, Barr E, Tamms GM, Zhou H, Reisinger KS (2010) Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccine. Pediatr Infect Dis J 29(2):95\u2013101","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"261_CR12","doi-asserted-by":"crossref","first-page":"5939","DOI":"10.1038\/s41598-018-24246-w","volume":"8","author":"ML Boisen","year":"2018","unstructured":"Boisen ML, Hartnett JN, Shaffer JG, Goba A, Momoh M, Sandi JD, Fullah M, Nelson DKS, Bush DJ, Rowland MM, Heinrich ML, Koval AP, Cross RW, Barnes KG, Lachenauer AE, Lin AE, Nekoui M, Kotliar D, Winnicki SM, Siddle KJ, Gbakie M, Fonnie M, Koroma VJ, Kanneh L, Kulakosky PC, Hastie KM, Wilson RB, Andersen KG, Folarin OO, Happi CT, Sabeti PC, Geisbert TW, Saphire EO, Khan SH, Grant DS, Schieffelin JS, Branco LM, Garry RF (2018) Field validation of recombinant antigen immunoassays for diagnosis of Lassa fever. Sci Rep 8(1):5939","journal-title":"Sci Rep"},{"key":"261_CR13","doi-asserted-by":"crossref","unstructured":"Borenstein-Katz A, Shulman A, Hamawi H, Leitner O, Diskin R (2019) Differential antibody-based immune response against isolated GP1 receptor-binding domains from Lassa and Jun\u00edn Viruses. J Virol 93(8)","DOI":"10.1128\/JVI.00090-19"},{"issue":"17","key":"261_CR14","doi-asserted-by":"crossref","first-page":"8351","DOI":"10.1128\/JVI.00896-06","volume":"80","author":"J Botten","year":"2006","unstructured":"Botten J, Alexander J, Pasquetto V, Sidney J, Barrowman P, Ting J, Peters B, Southwood S, Stewart B, Rodriguez-Carreno MP, Mothe B, Whitton JL, Sette A, Buchmeier MJ (2006) Identification of protective Lassa virus epitopes that are restricted by HLA-A2. J Virol 80(17):8351\u20138361","journal-title":"J Virol"},{"issue":"19","key":"261_CR15","doi-asserted-by":"crossref","first-page":"9947","DOI":"10.1128\/JVI.00672-10","volume":"84","author":"J Botten","year":"2010","unstructured":"Botten J, Whitton JL, Barrowman P, Sidney J, Whitmire JK, Alexander J, Kotturi MF, Sette A, Buchmeier MJ (2010) A multivalent vaccination strategy for the prevention of Old World arenavirus infection in humans. J Virol 84(19):9947\u20139956","journal-title":"J Virol"},{"issue":"15","key":"261_CR16","doi-asserted-by":"crossref","first-page":"6992","DOI":"10.1128\/JVI.74.15.6992-7004.2000","volume":"74","author":"MD Bowen","year":"2000","unstructured":"Bowen MD, Rollin PE, Ksiazek TG, Hustad HL, Bausch DG, Demby AH, Bajani MD, Peters CJ, Nichol ST (2000) Genetic diversity among Lassa virus strains. J Virol 74(15):6992\u20137004","journal-title":"J Virol"},{"key":"261_CR17","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1186\/1743-422X-8-478","volume":"8","author":"LM Branco","year":"2011","unstructured":"Branco LM, Grove JN, Boisen ML, Shaffer JG, Goba A, Fullah M, Momoh M, Grant DS, Garry RF (2011) Emerging trends in Lassa fever: redefining the role of immunoglobulin M and inflammation in diagnosing acute infection. Virol J 8:478","journal-title":"Virol J"},{"key":"261_CR18","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/1743-422X-7-279","volume":"7","author":"LM Branco","year":"2010","unstructured":"Branco LM, Grove JN, Geske FJ, Boisen ML, Muncy IJ, Magliato SA, Henderson LA, Schoepp RJ, Cashman KA, Hensley LE, Garry RF (2010) Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever. Virol J 7:279","journal-title":"Virol J"},{"issue":"2","key":"261_CR19","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.virol.2005.12.001","volume":"345","author":"PJ Bredenbeek","year":"2006","unstructured":"Bredenbeek PJ, Molenkamp R, Spaan WJ, Deubel V, Marianneau P, Salvato MS, Moshkoff D, Zapata J, Tikhonov I, Patterson J, Carrion R, Ticer A, Brasky K, Lukashevich IS (2006) A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins. Virology 345(2):299\u2013304","journal-title":"Virology"},{"key":"261_CR20","doi-asserted-by":"crossref","unstructured":"Brouillette RB, Phillips EK, Ayithan N, Maury W (2017) Differences in Glycoprotein complex receptor binding site accessibility prompt poor cross-reactivity of neutralizing antibodies between closely related arenaviruses. J Virol 91(7)","DOI":"10.1128\/JVI.01454-16"},{"key":"261_CR21","doi-asserted-by":"crossref","unstructured":"Cai Y, Ye C, Cheng B, Nogales A, Iwasaki M, Yu S, Cooper K, Liu DX, Hart R, Adams R, Brady T, Postnikova EN, Kurtz J, St Claire M, Kuhn JH, de la Torre JC, Mart\u00ednez-Sobrido L (2020) A Lassa fever live-attenuated vaccine based on codon deoptimization of the viral glycoprotein gene. mBio 11(1)","DOI":"10.1128\/mBio.00039-20"},{"key":"261_CR22","doi-asserted-by":"crossref","unstructured":"Carnec X, Mateo M, Page A, Reynard S, Hortion J, Picard C, Yekwa E, Barrot L, Barron S, Vallve A, Raoul H, Carbonnelle C, Ferron F, Baize S (2018) A vaccine platform against arenaviruses based on a recombinant hyperattenuated mopeia virus expressing heterologous glycoproteins. J Virol 92(12)","DOI":"10.1128\/JVI.02230-17"},{"issue":"20","key":"261_CR23","doi-asserted-by":"crossref","first-page":"4093","DOI":"10.1016\/j.vaccine.2007.02.038","volume":"25","author":"R Carrion Jr","year":"2007","unstructured":"Carrion R Jr, Patterson JL, Johnson C, Gonzales M, Moreira CR, Ticer A, Brasky K, Hubbard GB, Moshkoff D, Zapata J, Salvato MS, Lukashevich IS (2007) A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity. Vaccine 25(20):4093\u20134102","journal-title":"Vaccine"},{"issue":"3","key":"261_CR24","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3390\/vaccines1030262","volume":"1","author":"KA Cashman","year":"2013","unstructured":"Cashman KA, Broderick KE, Wilkinson ER, Shaia CI, Bell TM, Shurtleff AC, Spik KW, Badger CV, Guttieri MC, Sardesai NY, Schmaljohn CS (2013) Enhanced efficacy of a codon-optimized DNA vaccine encoding the glycoprotein precursor gene of Lassa virus in a guinea pig disease model when delivered by dermal electroporation. Vaccines 1(3):262\u2013277","journal-title":"Vaccines"},{"issue":"1","key":"261_CR25","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.antiviral.2011.02.012","volume":"90","author":"KA Cashman","year":"2011","unstructured":"Cashman KA, Smith MA, Twenhafel NA, Larson RA, Jones KF, Allen RD 3rd, Dai D, Chinsangaram J, Bolken TC, Hruby DE, Amberg SM, Hensley LE, Guttieri MC (2011) Evaluation of Lassa antiviral compound ST-193 in a guinea pig model. Antiviral Res 90(1):70\u201379","journal-title":"Antiviral Res"},{"issue":"12","key":"261_CR26","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1080\/21645515.2017.1356500","volume":"13","author":"KA Cashman","year":"2017","unstructured":"Cashman KA, Wilkinson ER, Shaia CI, Facemire PR, Bell TM, Bearss JJ, Shamblin JD, Wollen SE, Broderick KE, Sardesai NY, Schmaljohn CS (2017) A DNA vaccine delivered by dermal electroporation fully protects cynomolgus macaques against Lassa fever. Hum Vaccin Immunother 13(12):2902\u20132911","journal-title":"Hum Vaccin Immunother"},{"issue":"10","key":"261_CR27","doi-asserted-by":"crossref","first-page":"e0205884","DOI":"10.1371\/journal.pone.0205884","volume":"13","author":"NN Chidumayo","year":"2018","unstructured":"Chidumayo NN (2018) System dynamics modelling approach to explore the effect of dog demography on rabies vaccination coverage in Africa. PLoS ONE 13(10):e0205884","journal-title":"PLoS ONE"},{"issue":"9","key":"261_CR28","doi-asserted-by":"crossref","first-page":"4494","DOI":"10.1128\/JVI.00103-16","volume":"90","author":"YY Chou","year":"2016","unstructured":"Chou YY, Cuevas C, Carocci M, Stubbs SH, Ma M, Cureton DK, Chao L, Evesson F, He K, Yang PL, Whelan SP, Ross SR, Kirchhausen T, Gaudin R (2016) Identification and characterization of a novel broad-spectrum virus entry inhibitor. J Virol 90(9):4494\u20134510","journal-title":"J Virol"},{"issue":"1","key":"261_CR29","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1038\/s41467-018-04271-z","volume":"9","author":"LE Clark","year":"2018","unstructured":"Clark LE, Mahmutovic S, Raymond DD, Dilanyan T, Koma T, Manning JT, Shankar S, Levis SC, Briggiler AM, Enria DA, Wucherpfennig KW, Paessler S, Abraham J (2018) Vaccine-elicited receptor-binding site antibodies neutralize two new world hemorrhagic fever arenaviruses. Nat Commun 9(1):1884","journal-title":"Nat Commun"},{"issue":"8552","key":"261_CR30","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(87)90767-7","volume":"2","author":"JC Clegg","year":"1987","unstructured":"Clegg JC, Lloyd G (1987) Vaccinia recombinant expressing Lassa-virus internal nucleocapsid protein protects guineapigs against Lassa fever. Lancet 2(8552):186\u2013188","journal-title":"Lancet"},{"issue":"2\u20133","key":"261_CR31","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0168-1702(91)90015-N","volume":"18","author":"JC Clegg","year":"1991","unstructured":"Clegg JC, Wilson SM, Oram JD (1991) Nucleotide sequence of the S RNA of Lassa virus (Nigerian strain) and comparative analysis of arenavirus gene products. Virus Res 18(2\u20133):151\u2013164","journal-title":"Virus Res"},{"issue":"1","key":"261_CR32","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41467-019-13924-6","volume":"11","author":"H Cohen-Dvashi","year":"2020","unstructured":"Cohen-Dvashi H, Amon R, Agans KN, Cross RW, Borenstein-Katz A, Mateo M, Baize S, Padler-Karavani V, Geisbert TW, Diskin R (2020) Rational design of universal immunotherapy for TfR1-tropic arenaviruses. Nat Commun 11(1):67","journal-title":"Nat Commun"},{"issue":"5","key":"261_CR33","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1159\/000149136","volume":"13","author":"B Cresta","year":"1980","unstructured":"Cresta B, Padula P, de Martinez Segovia M (1980) Biological properties of Junin virus proteins. I. Identification of the immunogenic glycoprotein. Intervirology 13(5):284\u2013288","journal-title":"Intervirology"},{"key":"261_CR34","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.coviro.2019.07.003","volume":"37","author":"RW Cross","year":"2019","unstructured":"Cross RW, Hastie KM, Mire CE, Robinson JE, Geisbert TW, Branco LM, Ollmann Saphire E, Garry RF (2019) Antibody therapy for Lassa fever. Curr Opin Virol 37:97\u2013104","journal-title":"Curr Opin Virol"},{"key":"261_CR35","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.antiviral.2016.08.012","volume":"133","author":"RW Cross","year":"2016","unstructured":"Cross RW, Mire CE, Branco LM, Geisbert JB, Rowland MM, Heinrich ML, Goba A, Momoh M, Grant DS, Fullah M, Khan SH, Robinson JE, Geisbert TW, Garry RF (2016) Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies. Antiviral Res 133:218\u2013222","journal-title":"Antiviral Res"},{"issue":"1","key":"261_CR36","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1172\/JCI131958","volume":"130","author":"RW Cross","year":"2020","unstructured":"Cross RW, Xu R, Matassov D, Hamm S, Latham TE, Gerardi CS, Nowak RM, Geisbert JB, Ota-Setlik A, Agans KN, Luckay A, Witko SE, Soukieh L, Deer DJ, Mire CE, Feldmann H, Happi C, Fenton KA, Eldridge JH, Geisbert TW (2020) Quadrivalent VesiculoVax vaccine protects nonhuman primates from viral-induced hemorrhagic fever and death. J Clin Invest 130(1):539\u2013551","journal-title":"J Clin Invest"},{"issue":"784","key":"261_CR37","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1136\/pgmj.67.784.193","volume":"67","author":"D Cummins","year":"1991","unstructured":"Cummins D, Bennett D, Machin SJ (1991) Exchange transfusion of a patient with fulminant Lassa fever. Postgrad Med J 67(784):193\u2013194","journal-title":"Postgrad Med J"},{"key":"261_CR38","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.antiviral.2018.03.003","volume":"153","author":"L Delang","year":"2018","unstructured":"Delang L, Abdelnabi R, Neyts J (2018) Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antiviral Res 153:85\u201394","journal-title":"Antiviral Res"},{"issue":"12","key":"261_CR39","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1128\/jcm.32.12.2898-2903.1994","volume":"32","author":"AH Demby","year":"1994","unstructured":"Demby AH, Chamberlain J, Brown DW, Clegg CS (1994) Early diagnosis of Lassa fever by reverse transcription-PCR. J Clin Microbiol 32(12):2898\u20132903","journal-title":"J Clin Microbiol"},{"issue":"2","key":"261_CR40","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1006\/viro.1997.8722","volume":"235","author":"M Djavani","year":"1997","unstructured":"Djavani M, Lukashevich IS, Sanchez A, Nichol ST, Salvato MS (1997) Completion of the Lassa fever virus sequence and identification of a RING finger open reading frame at the L RNA 5\u2019 end. Virology 235(2):414\u2013418","journal-title":"Virology"},{"issue":"1\u20132","key":"261_CR41","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0166-3542(02)00201-2","volume":"57","author":"C Drosten","year":"2003","unstructured":"Drosten C, K\u00fcmmerer BM, Schmitz H, G\u00fcnther S (2003) Molecular diagnostics of viral hemorrhagic fevers. Antiviral Res 57(1\u20132):61\u201387","journal-title":"Antiviral Res"},{"key":"261_CR42","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ijid.2019.07.015","volume":"87","author":"KA Eberhardt","year":"2019","unstructured":"Eberhardt KA, Mischlinger J, Jordan S, Groger M, G\u00fcnther S, Ramharter M (2019) Ribavirin for the treatment of Lassa fever: a systematic review and meta-analysis. Int J Infect Dis 87:15\u201320","journal-title":"Int J Infect Dis"},{"issue":"1","key":"261_CR43","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s10157-017-1416-7","volume":"22","author":"E Elhanan","year":"2018","unstructured":"Elhanan E, Boaz M, Schwartz I, Schwartz D, Chernin G, Soetendorp H, Gal Oz A, Agbaria A, Weinstein T (2018) A randomized, controlled clinical trial to evaluate the immunogenicity of a PreS\/S hepatitis B vaccine Sci-B-Vac\u2122, as compared to Engerix B(\u00ae), among vaccine na\u00efve and vaccine non-responder dialysis patients. Clin Exp Nephrol 22(1):151\u2013158","journal-title":"Clin Exp Nephrol"},{"issue":"3","key":"261_CR44","first-page":"215","volume":"70","author":"DA Enria","year":"2010","unstructured":"Enria DA, Ambrosio AM, Briggiler AM, Feuillade MR, Crivelli E (2010) Candid#1 vaccine against argentine hemorrhagic fever produced in Argentina. Immunogenicity and safety. Medicina (b Aires) 70(3):215\u2013222","journal-title":"Medicina (b Aires)"},{"key":"261_CR45","first-page":"239","volume":"263","author":"DA Enria","year":"2002","unstructured":"Enria DA, Barrera Oro JG (2002) Junin virus vaccines. Curr Top Microbiol Immunol 263:239\u2013261","journal-title":"Curr Top Microbiol Immunol"},{"issue":"8397","key":"261_CR46","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(84)90299-X","volume":"2","author":"DA Enria","year":"1984","unstructured":"Enria DA, Briggiler AM, Fernandez NJ, Levis SC, Maiztegui JI (1984) Importance of dose of neutralising antibodies in treatment of Argentine haemorrhagic fever with immune plasma. Lancet 2(8397):255\u2013256","journal-title":"Lancet"},{"issue":"1","key":"261_CR47","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.antiviral.2007.10.010","volume":"78","author":"DA Enria","year":"2008","unstructured":"Enria DA, Briggiler AM, S\u00e1nchez Z (2008) Treatment of Argentine hemorrhagic fever. Antiviral Res 78(1):132\u2013139","journal-title":"Antiviral Res"},{"issue":"1","key":"261_CR48","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0166-3542(94)90030-2","volume":"23","author":"DA Enria","year":"1994","unstructured":"Enria DA, Maiztegui JI (1994) Antiviral treatment of Argentine hemorrhagic fever. Antiviral Res 23(1):23\u201331","journal-title":"Antiviral Res"},{"issue":"3","key":"261_CR49","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.coviro.2013.04.007","volume":"3","author":"D Falzarano","year":"2013","unstructured":"Falzarano D, Feldmann H (2013) Vaccines for viral hemorrhagic fevers-progress and shortcomings. Curr Opin Virol 3(3):343\u2013351","journal-title":"Curr Opin Virol"},{"issue":"7053","key":"261_CR50","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature04082","volume":"436","author":"JJ Feld","year":"2005","unstructured":"Feld JJ, Hoofnagle JH (2005) Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436(7053):967\u2013972","journal-title":"Nature"},{"issue":"1","key":"261_CR51","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41541-021-00291-x","volume":"6","author":"RJ Fischer","year":"2021","unstructured":"Fischer RJ, Purushotham JN, van Doremalen N, Sebastian S, Meade-White K, Cordova K, Letko M, Jeremiah Matson M, Feldmann F, Haddock E, LaCasse R, Saturday G, Lambe T, Gilbert SC, Munster VJ (2021) ChAdOx1-vectored Lassa fever vaccine elicits a robust cellular and humoral immune response and protects guinea pigs against lethal Lassa virus challenge. NPJ Vaccines 6(1):32","journal-title":"NPJ Vaccines"},{"issue":"15","key":"261_CR52","doi-asserted-by":"crossref","first-page":"6777","DOI":"10.1128\/JVI.74.15.6777-6783.2000","volume":"74","author":"SP Fisher-Hoch","year":"2000","unstructured":"Fisher-Hoch SP, Hutwagner L, Brown B, McCormick JB (2000) Effective vaccine for Lassa fever. J Virol 74(15):6777\u20136783","journal-title":"J Virol"},{"issue":"2","key":"261_CR53","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1586\/14760584.3.2.189","volume":"3","author":"SP Fisher-Hoch","year":"2004","unstructured":"Fisher-Hoch SP, McCormick JB (2004) Lassa fever vaccine. Expert Rev Vaccines 3(2):189\u2013197","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"261_CR54","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1073\/pnas.86.1.317","volume":"86","author":"SP Fisher-Hoch","year":"1989","unstructured":"Fisher-Hoch SP, McCormick JB, Auperin D, Brown BG, Castor M, Perez G, Ruo S, Conaty A, Brammer L, Bauer S (1989) Protection of rhesus monkeys from fatal Lassa fever by vaccination with a recombinant vaccinia virus containing the Lassa virus glycoprotein gene. Proc Natl Acad Sci USA 86(1):317\u2013321","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"261_CR55","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0035-9203(84)90107-X","volume":"78","author":"JD Frame","year":"1984","unstructured":"Frame JD, Verbrugge GP, Gill RG, Pinneo L (1984) The use of Lassa fever convalescent plasma in Nigeria. Trans R Soc Trop Med Hyg 78(3):319\u2013324","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"9\u201310","key":"261_CR56","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.micinf.2018.01.005","volume":"20","author":"PN Frantz","year":"2018","unstructured":"Frantz PN, Teeravechyan S, Tangy F (2018) Measles-derived vaccines to prevent emerging viral diseases. Microbes Infect 20(9\u201310):493\u2013500","journal-title":"Microbes Infect"},{"issue":"7","key":"261_CR57","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2183\/pjab.93.027","volume":"93","author":"Y Furuta","year":"2017","unstructured":"Furuta Y, Komeno T, Nakamura T (2017) Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci 93(7):449\u2013463","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"issue":"3","key":"261_CR58","doi-asserted-by":"crossref","first-page":"e0006361","DOI":"10.1371\/journal.pntd.0006361","volume":"12","author":"M Gabriel","year":"2018","unstructured":"Gabriel M, Adomeh DI, Ehimuan J, Oyakhilome J, Omomoh EO, Ighodalo Y, Olokor T, Bonney K, Pahlmann M, Emmerich P, Lelke M, Brunotte L, \u00d6lschl\u00e4ger S, Thom\u00e9-Bolduan C, Becker-Ziaja B, Busch C, Odia I, Ogbaini-Emovon E, Okokhere PO, Okogbenin SA, Akpede GO, Schmitz H, Asogun DA, G\u00fcnther S (2018) Development and evaluation of antibody-capture immunoassays for detection of Lassa virus nucleoprotein-specific immunoglobulin M and G. PLoS Negl Trop Dis 12(3):e0006361","journal-title":"PLoS Negl Trop Dis"},{"issue":"6","key":"261_CR59","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1371\/journal.pmed.0020183","volume":"2","author":"TW Geisbert","year":"2005","unstructured":"Geisbert TW, Jones S, Fritz EA, Shurtleff AC, Geisbert JB, Liebscher R, Grolla A, Str\u00f6her U, Fernando L, Daddario KM, Guttieri MC, Moth\u00e9 BR, Larsen T, Hensley LE, Jahrling PB, Feldmann H (2005) Development of a new vaccine for the prevention of Lassa fever. PLoS Med 2(6):e183","journal-title":"PLoS Med"},{"issue":"8","key":"261_CR60","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.vaccine.2011.12.134","volume":"30","author":"MA Goicochea","year":"2012","unstructured":"Goicochea MA, Zapata JC, Bryant J, Davis H, Salvato MS, Lukashevich IS (2012) Evaluation of Lassa virus vaccine immunogenicity in a CBA\/J-ML29 mouse model. Vaccine 30(8):1445\u20131452","journal-title":"Vaccine"},{"issue":"14","key":"261_CR61","doi-asserted-by":"crossref","first-page":"e0039721","DOI":"10.1128\/JVI.00397-21","volume":"95","author":"BB Gowen","year":"2021","unstructured":"Gowen BB, Hickerson BT, York J, Westover JB, Sefing EJ, Bailey KW, Wandersee L, Nunberg JH (2021a) Second-Generation Live-Attenuated Candid#1 vaccine virus resists reversion and protects against lethal Jun\u00edn virus infection in guinea pigs. J Virol 95(14):e0039721","journal-title":"J Virol"},{"key":"261_CR62","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/1743-422X-7-240","volume":"7","author":"BB Gowen","year":"2010","unstructured":"Gowen BB, Julander JG, London NR, Wong MH, Larson D, Morrey JD, Li DY, Bray M (2010) Assessing changes in vascular permeability in a hamster model of viral hemorrhagic fever. Virol J 7:240","journal-title":"Virol J"},{"key":"261_CR63","doi-asserted-by":"crossref","first-page":"105125","DOI":"10.1016\/j.antiviral.2021.105125","volume":"193","author":"BB Gowen","year":"2021","unstructured":"Gowen BB, Naik S, Westover JB, Brown ER, Gantla VR, Fetsko A, Dagley AL, Blotter DJ, Anderson N, McCormack K, Henkel G (2021b) Potent inhibition of arenavirus infection by a novel fusion inhibitor. Antiviral Res 193:105125","journal-title":"Antiviral Res"},{"issue":"9","key":"261_CR64","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1128\/AAC.00356-07","volume":"51","author":"BB Gowen","year":"2007","unstructured":"Gowen BB, Wong MH, Jung KH, Sanders AB, Mendenhall M, Bailey KW, Furuta Y, Sidwell RW (2007) In vitro and in vivo activities of T-705 against arenavirus and Bunyavirus infections. Antimicrob Agents Chemother 51(9):3168\u20133176","journal-title":"Antimicrob Agents Chemother"},{"issue":"6341","key":"261_CR65","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1126\/science.aam7260","volume":"356","author":"KM Hastie","year":"2017","unstructured":"Hastie KM, Zandonatti MA, Kleinfelter LM, Heinrich ML, Rowland MM, Chandran K, Branco LM, Robinson JE, Garry RF, Saphire EO (2017) Structural basis for antibody-mediated neutralization of Lassa virus. Science 356(6341):923\u2013928","journal-title":"Science"},{"issue":"7","key":"261_CR66","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1128\/JVI.06397-11","volume":"86","author":"G Helguera","year":"2012","unstructured":"Helguera G, Jemielity S, Abraham J, Cordo SM, Martinez MG, Rodr\u00edguez JA, Bregni C, Wang JJ, Farzan M, Penichet ML, Candurra NA, Choe H (2012) An antibody recognizing the apical domain of human transferrin receptor 1 efficiently inhibits the entry of all new world hemorrhagic fever arenaviruses. J Virol 86(7):4024\u20134028","journal-title":"J Virol"},{"issue":"8","key":"261_CR67","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S1473-3099(17)30313-4","volume":"17","author":"DG Heppner Jr","year":"2017","unstructured":"Heppner DG Jr, Kemp TL, Martin BK, Ramsey WJ, Nichols R, Dasen EJ, Link CJ, Das R, Xu ZJ, Sheldon EA, Nowak TA, Monath TP (2017) Safety and immunogenicity of the rVSV\u2206G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study. Lancet Infect Dis 17(8):854\u2013866","journal-title":"Lancet Infect Dis"},{"key":"261_CR68","doi-asserted-by":"crossref","unstructured":"Hulseberg CE, F\u00e9n\u00e9ant L, Szyma\u0144ska-de Wijs KM, Kessler NP, Nelson EA, Shoemaker CJ, Schmaljohn CS, Polyak SJ, White JM (2019) Arbidol and other low-molecular-weight drugs that inhibit Lassa and Ebola viruses. J Virol 93(8)","DOI":"10.1128\/JVI.02185-18"},{"issue":"2","key":"261_CR69","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/jmv.1890120203","volume":"12","author":"PB Jahrling","year":"1983","unstructured":"Jahrling PB (1983) Protection of Lassa virus-infected guinea pigs with Lassa-immune plasma of guinea pig, primate, and human origin. J Med Virol 12(2):93\u2013102","journal-title":"J Med Virol"},{"issue":"3","key":"261_CR70","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/0035-9203(85)90388-8","volume":"79","author":"PB Jahrling","year":"1985","unstructured":"Jahrling PB, Frame JD, Rhoderick JB, Monson MH (1985) Endemic Lassa fever in Liberia. IV. Selection of optimally effective plasma for treatment by passive immunization. Trans R Soc Trop Med Hyg 79(3):380\u2013384","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"3","key":"261_CR71","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/infdis\/149.3.420","volume":"149","author":"PB Jahrling","year":"1984","unstructured":"Jahrling PB, Peters CJ, Stephen EL (1984) Enhanced treatment of Lassa fever by immune plasma combined with ribavirin in cynomolgus monkeys. J Infect Dis 149(3):420\u2013427","journal-title":"J Infect Dis"},{"issue":"9","key":"261_CR72","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1080\/21645515.2019.1616499","volume":"15","author":"J Jiang","year":"2019","unstructured":"Jiang J, Banglore P, Cashman KA, Schmaljohn CS, Schultheis K, Pugh H, Nguyen J, Humeau LM, Broderick KE, Ramos SJ (2019) Immunogenicity of a protective intradermal DNA vaccine against Lassa virus in cynomolgus macaques. Hum Vaccin Immunother 15(9):2066\u20132074","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"261_CR73","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.vaccine.2010.11.079","volume":"29","author":"X Jiang","year":"2011","unstructured":"Jiang X, Dalebout TJ, Bredenbeek PJ, Carrion R Jr, Brasky K, Patterson J, Goicochea M, Bryant J, Salvato MS, Lukashevich IS (2011) Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs. Vaccine 29(6):1248\u20131257","journal-title":"Vaccine"},{"key":"261_CR74","doi-asserted-by":"crossref","unstructured":"Johnson DM, Sokoloski KJ, Jokinen JD, Pfeffer TL, Chu YK, Adcock RS, Chung D, Tretyakova I, Pushko P, Lukashevich IS (2020) Advanced safety and genetic stability in mice of a novel DNA-launched venezuelan equine Encephalitis virus vaccine with rearranged structural genes. Vaccines 8(1)","DOI":"10.3390\/vaccines8010114"},{"issue":"3","key":"261_CR75","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1093\/infdis\/155.3.456","volume":"155","author":"KM Johnson","year":"1987","unstructured":"Johnson KM, McCormick JB, Webb PA, Smith ES, Elliott LH, King IJ (1987) Clinical virology of Lassa fever in hospitalized patients. J Infect Dis 155(3):456\u2013464","journal-title":"J Infect Dis"},{"issue":"3","key":"261_CR76","first-page":"353","volume":"380","author":"CY Kang","year":"1999","unstructured":"Kang CY, Luo L, Wainberg MA, Li Y (1999) Development of HIV\/AIDS vaccine using chimeric Gag-Env virus-like particles. Biol Chem 380(3):353\u2013364","journal-title":"Biol Chem"},{"issue":"6073","key":"261_CR77","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1136\/bmj.1.6073.1399","volume":"1","author":"E Keane","year":"1977","unstructured":"Keane E, Gilles HM (1977) Lassa fever in Panguma Hospital, Sierra Leone, 1973\u20136. Br Med J 1(6073):1399\u20131402","journal-title":"Br Med J"},{"issue":"8145","key":"261_CR78","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S0140-6736(79)90659-7","volume":"2","author":"MP Kiley","year":"1979","unstructured":"Kiley MP, Lange JV, Johnson KM (1979) Protection of rhesus monkeys from Lassa virus by immunisation with closely related Arenavirus. Lancet 2(8145):738","journal-title":"Lancet"},{"issue":"12","key":"261_CR79","doi-asserted-by":"crossref","first-page":"e1000695","DOI":"10.1371\/journal.ppat.1000695","volume":"5","author":"MF Kotturi","year":"2009","unstructured":"Kotturi MF, Botten J, Sidney J, Bui HH, Giancola L, Maybeno M, Babin J, Oseroff C, Pasquetto V, Greenbaum JA, Peters B, Ting J, Do D, Vang L, Alexander J, Grey H, Buchmeier MJ, Sette A (2009) A multivalent and cross-protective vaccine strategy against arenaviruses associated with human disease. PLoS Pathog 5(12):e1000695","journal-title":"PLoS Pathog"},{"issue":"6","key":"261_CR80","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/infdis\/jiab014","volume":"224","author":"D Kurup","year":"2021","unstructured":"Kurup D, Fisher CR, Scher G, Yankowski C, Testa A, Keshwara R, Abreu-Mota T, Lambert R, Ferguson M, Rinaldi W, Ruiz L, Wirblich C, Schnell MJ (2021) Tetravalent rabies-vectored filovirus and Lassa fever vaccine induces long-term immunity in nonhuman primates. J Infect Dis 224(6):995\u20131004","journal-title":"J Infect Dis"},{"issue":"21","key":"261_CR81","doi-asserted-by":"crossref","first-page":"10768","DOI":"10.1128\/JVI.00941-08","volume":"82","author":"RA Larson","year":"2008","unstructured":"Larson RA, Dai D, Hosack VT, Tan Y, Bolken TC, Hruby DE, Amberg SM (2008) Identification of a broad-spectrum arenavirus entry inhibitor. J Virol 82(21):10768\u201310775","journal-title":"J Virol"},{"issue":"5","key":"261_CR82","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1053\/jhep.2002.32672","volume":"35","author":"JY Lau","year":"2002","unstructured":"Lau JY, Tam RC, Liang TJ, Hong Z (2002) Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 35(5):1002\u20131009","journal-title":"Hepatology"},{"issue":"4","key":"261_CR83","doi-asserted-by":"crossref","first-page":"677","DOI":"10.4269\/ajtmh.1970.19.677","volume":"19","author":"E Leifer","year":"1970","unstructured":"Leifer E, Gocke DJ, Bourne H (1970) Lassa fever, a new virus disease of man from West Africa. II. Report of a laboratory-acquired infection treated with plasma from a person recently recovered from the disease. Am J Trop Med Hyg 19(4):677\u2013679","journal-title":"Am J Trop Med Hyg"},{"issue":"2","key":"261_CR84","doi-asserted-by":"crossref","first-page":"e1005418","DOI":"10.1371\/journal.ppat.1005418","volume":"12","author":"S Li","year":"2016","unstructured":"Li S, Sun Z, Pryce R, Parsy ML, Fehling SK, Schlie K, Siebert CA, Garten W, Bowden TA, Strecker T, Huiskonen JT (2016) Acidic pH-induced conformations and LAMP1 binding of the Lassa virus glycoprotein spike. PLoS Pathog 12(2):e1005418","journal-title":"PLoS Pathog"},{"issue":"12","key":"261_CR85","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1038\/nbt1291-1356","volume":"9","author":"P Liljestr\u00f6m","year":"1991","unstructured":"Liljestr\u00f6m P, Garoff H (1991) A new generation of animal cell expression vectors based on the semliki forest virus replicon. Biotechnology 9(12):1356\u20131361","journal-title":"Biotechnology"},{"issue":"1","key":"261_CR86","doi-asserted-by":"crossref","first-page":"e1008535","DOI":"10.1371\/journal.pcbi.1008535","volume":"17","author":"G Lingas","year":"2021","unstructured":"Lingas G, Rosenke K, Safronetz D, Guedj J (2021) Lassa viral dynamics in non-human primates treated with favipiravir or ribavirin. PLoS Comput Biol 17(1):e1008535","journal-title":"PLoS Comput Biol"},{"issue":"1","key":"261_CR87","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1038\/s41467-018-04859-5","volume":"9","author":"C L\u00f3pez-Camacho","year":"2018","unstructured":"L\u00f3pez-Camacho C, Abbink P, Larocca RA, Dejnirattisai W, Boyd M, Badamchi-Zadeh A, Wallace ZR, Doig J, Velazquez RS, Neto RDL, Coelho DF, Kim YC, Donald CL, Owsianka A, De Lorenzo G, Kohl A, Gilbert SC, Dorrell L, Mongkolsapaya J, Patel AH, Screaton GR, Barouch DH, Hill AVS, Reyes-Sandoval A (2018) Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors. Nat Commun 9(1):2441","journal-title":"Nat Commun"},{"issue":"2","key":"261_CR88","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/0042-6822(92)90514-P","volume":"188","author":"IS Lukashevich","year":"1992","unstructured":"Lukashevich IS (1992) Generation of reassortants between African arenaviruses. Virology 188(2):600\u2013605","journal-title":"Virology"},{"issue":"11","key":"261_CR89","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.3390\/v4112514","volume":"4","author":"IS Lukashevich","year":"2012","unstructured":"Lukashevich IS (2012) Advanced vaccine candidates for Lassa fever. Viruses 4(11):2514\u20132557","journal-title":"Viruses"},{"issue":"41","key":"261_CR90","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.1016\/j.vaccine.2008.07.057","volume":"26","author":"IS Lukashevich","year":"2008","unstructured":"Lukashevich IS, Carrion R Jr, Salvato MS, Mansfield K, Brasky K, Zapata J, Cairo C, Goicochea M, Hoosien GE, Ticer A, Bryant J, Davis H, Hammamieh R, Mayda M, Jett M, Patterson J (2008) Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates. Vaccine 26(41):5246\u20135254","journal-title":"Vaccine"},{"key":"261_CR91","doi-asserted-by":"crossref","unstructured":"Lukashevich IS, Djavani M, Shapiro K, Sanchez A, Ravkov E, Nichol ST, Salvato MS (1997) The Lassa fever virus L gene: nucleotide sequence, comparison, and precipitation of a predicted 250 kDa protein with monospecific antiserum. J Gen Virol 78(Pt 3):547\u2013551","DOI":"10.1099\/0022-1317-78-3-547"},{"issue":"22","key":"261_CR92","doi-asserted-by":"crossref","first-page":"13934","DOI":"10.1128\/JVI.79.22.13934-13942.2005","volume":"79","author":"IS Lukashevich","year":"2005","unstructured":"Lukashevich IS, Patterson J, Carrion R, Moshkoff D, Ticer A, Zapata J, Brasky K, Geiger R, Hubbard GB, Bryant J, Salvato MS (2005) A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses. J Virol 79(22):13934\u201313942","journal-title":"J Virol"},{"issue":"12","key":"261_CR93","doi-asserted-by":"crossref","first-page":"e1007439","DOI":"10.1371\/journal.ppat.1007439","volume":"14","author":"IG Madu","year":"2018","unstructured":"Madu IG, Files M, Gharaibeh DN, Moore AL, Jung KH, Gowen BB, Dai D, Jones KF, Tyavanagimatt SR, Burgeson JR, Korth MJ, Bedard KM, Iadonato SP, Amberg SM (2018) A potent Lassa virus antiviral targets an arenavirus virulence determinant. PLoS Pathog 14(12):e1007439","journal-title":"PLoS Pathog"},{"issue":"42","key":"261_CR94","doi-asserted-by":"crossref","first-page":"5393","DOI":"10.1016\/j.vaccine.2008.07.084","volume":"26","author":"K Mahmood","year":"2008","unstructured":"Mahmood K, Bright RA, Mytle N, Carter DM, Crevar CJ, Achenbach JE, Heaton PM, Tumpey TM, Ross TM (2008) H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Vaccine 26(42):5393\u20135399","journal-title":"Vaccine"},{"issue":"8154","key":"261_CR95","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/S0140-6736(79)92335-3","volume":"2","author":"JI Maiztegui","year":"1979","unstructured":"Maiztegui JI, Fernandez NJ, de Damilano AJ (1979) Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome. Lancet 2(8154):1216\u20131217","journal-title":"Lancet"},{"key":"261_CR96","doi-asserted-by":"crossref","unstructured":"Matassov D, Mire CE, Latham T, Geisbert JB, Xu R, Ota-Setlik A, Agans KN, Kobs DJ, Wendling MQS, Burnaugh A, Rudge TL, Jr, Sabourin CL, Egan MA, Clarke DK, Geisbert TW, Eldridge JH (2018) Single-dose trivalent VesiculoVax vaccine protects macaques from lethal Ebolavirus and marburgvirus challenge. J Virol 92(3)","DOI":"10.1128\/JVI.01190-17"},{"key":"261_CR97","doi-asserted-by":"crossref","unstructured":"Mateo M, Reynard S, Carnec X, Journeaux A, Baillet N, Schaeffer J, Picard C, Legras-Lachuer C, Allan R, Perthame E, Hillion KH, Pietrosemoli N, Dillies MA, Barrot L, Vallve A, Barron S, Fellmann L, Gaillard JC, Armengaud J, Carbonnelle C, Raoul H, Tangy F, Baize S (2019) Vaccines inducing immunity to Lassa virus glycoprotein and nucleoprotein protect macaques after a single shot. Sci Transl Med 11(512)","DOI":"10.1126\/scitranslmed.aaw3163"},{"key":"261_CR98","doi-asserted-by":"crossref","unstructured":"Mateo M, Reynard S, Journeaux A, Germain C, Hortion J, Carnec X, Picard C, Baillet N, Borges-Cardoso V, Merabet O, Vallve A, Barron S, Jourjon O, Lacroix O, Duthey A, Dirheimer M, Jouvion G, Moreau PH, Fellmann L, Carbonnelle C, Raoul H, Tangy F, Baize S (2021) A single-shot Lassa vaccine induces long-term immunity and protects cynomolgus monkeys against heterologous strains. Sci Transl Med 13(597)","DOI":"10.1126\/scitranslmed.abf6348"},{"key":"261_CR99","first-page":"75","volume":"262","author":"JB McCormick","year":"2002","unstructured":"McCormick JB, Fisher-Hoch SP (2002) Lassa fever. Curr Top Microbiol Immunol 262:75\u2013109","journal-title":"Curr Top Microbiol Immunol"},{"issue":"1","key":"261_CR100","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJM198601023140104","volume":"314","author":"JB McCormick","year":"1986","unstructured":"McCormick JB, King IJ, Webb PA, Scribner CL, Craven RB, Johnson KM, Elliott LH, Belmont-Williams R (1986) Lassa fever. Effective therapy with ribavirin. N Engl J Med 314(1):20\u201326","journal-title":"N Engl J Med"},{"issue":"1","key":"261_CR101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jmv.1890370102","volume":"37","author":"JB McCormick","year":"1992","unstructured":"McCormick JB, Mitchell SW, Kiley MP, Ruo S, Fisher-Hoch SP (1992) Inactivated Lassa virus elicits a non protective immune response in rhesus monkeys. J Med Virol 37(1):1\u20137","journal-title":"J Med Virol"},{"issue":"3","key":"261_CR102","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/infdis\/155.3.437","volume":"155","author":"JB McCormick","year":"1987","unstructured":"McCormick JB, Webb PA, Krebs JW, Johnson KM, Smith ES (1987) A prospective study of the epidemiology and ecology of Lassa fever. J Infect Dis 155(3):437\u2013444","journal-title":"J Infect Dis"},{"issue":"1","key":"261_CR103","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1128\/JVI.77.1.237-244.2003","volume":"77","author":"JP McGettigan","year":"2003","unstructured":"McGettigan JP, Pomerantz RJ, Siler CA, McKenna PM, Foley HD, Dietzschold B, Schnell MJ (2003) Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 gag have greatly reduced pathogenicity but are highly immunogenic. J Virol 77(1):237\u2013244","journal-title":"J Virol"},{"issue":"3","key":"261_CR104","doi-asserted-by":"crossref","first-page":"403","DOI":"10.4269\/ajtmh.1993.48.403","volume":"48","author":"KT McKee Jr","year":"1993","unstructured":"McKee KT Jr, Oro JG, Kuehne AI, Spisso JA, Mahlandt BG (1993) Safety and immunogenicity of a live-attenuated Junin (Argentine hemorrhagic fever) vaccine in rhesus macaques. Am J Trop Med Hyg 48(3):403\u2013411","journal-title":"Am J Trop Med Hyg"},{"issue":"7","key":"261_CR105","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1111\/IGC.0b013e3181a3d100","volume":"19","author":"LR Medeiros","year":"2009","unstructured":"Medeiros LR, Rosa DD, da Rosa MI, Bozzetti MC, Zanini RR (2009) Efficacy of human papillomavirus vaccines: a systematic quantitative review. Int J Gynecol Cancer 19(7):1166\u20131176","journal-title":"Int J Gynecol Cancer"},{"issue":"10","key":"261_CR106","doi-asserted-by":"crossref","first-page":"e1342","DOI":"10.1371\/journal.pntd.0001342","volume":"5","author":"M Mendenhall","year":"2011","unstructured":"Mendenhall M, Russell A, Smee DF, Hall JO, Skirpstunas R, Furuta Y, Gowen BB (2011) Effective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic Fever. PLoS Negl Trop Dis 5(10):e1342","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"261_CR107","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.virol.2003.12.013","volume":"321","author":"J Meulen","year":"2004","unstructured":"Meulen J, Badusche M, Satoguina J, Strecker T, Lenz O, Loeliger C, Sakho M, Koulemou K, Koivogui L, Hoerauf A (2004) Old and New World arenaviruses share a highly conserved epitope in the fusion domain of the glycoprotein 2, which is recognized by Lassa virus-specific human CD4+ T-cell clones. Virology 321(1):134\u2013143","journal-title":"Virology"},{"issue":"20","key":"261_CR108","doi-asserted-by":"crossref","first-page":"4369","DOI":"10.1016\/j.vaccine.2006.02.051","volume":"24","author":"M Mihailova","year":"2006","unstructured":"Mihailova M, Boos M, Petrovskis I, Ose V, Skrastina D, Fiedler M, Sominskaya I, Ross S, Pumpens P, Roggendorf M, Viazov S (2006) Recombinant virus-like particles as a carrier of B- and T-cell epitopes of hepatitis C virus (HCV). Vaccine 24(20):4369\u20134377","journal-title":"Vaccine"},{"issue":"10","key":"261_CR109","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1038\/nm.4396","volume":"23","author":"CE Mire","year":"2017","unstructured":"Mire CE, Cross RW, Geisbert JB, Borisevich V, Agans KN, Deer DJ, Heinrich ML, Rowland MM, Goba A, Momoh M, Boisen ML, Grant DS, Fullah M, Khan SH, Fenton KA, Robinson JE, Branco LM, Garry RF, Geisbert TW (2017) Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever. Nat Med 23(10):1146\u20131149","journal-title":"Nat Med"},{"issue":"7549","key":"261_CR110","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/nature14428","volume":"520","author":"CE Mire","year":"2015","unstructured":"Mire CE, Matassov D, Geisbert JB, Latham TE, Agans KN, Xu R, Ota-Setlik A, Egan MA, Fenton KA, Clarke DK, Eldridge JH, Geisbert TW (2015) Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus. Nature 520(7549):688\u2013691","journal-title":"Nature"},{"issue":"1","key":"261_CR111","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0042-6822(89)90525-4","volume":"171","author":"HG Morrison","year":"1989","unstructured":"Morrison HG, Bauer SP, Lange JV, Esposito JJ, McCormick JB, Auperin DD (1989) Protection of guinea pigs from Lassa fever by vaccinia virus recombinants expressing the nucleoprotein or the envelope glycoproteins of Lassa virus. Virology 171(1):179\u2013188","journal-title":"Virology"},{"issue":"2","key":"261_CR112","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s11262-006-0050-3","volume":"34","author":"DA Moshkoff","year":"2007","unstructured":"Moshkoff DA, Salvato MS, Lukashevich IS (2007) Molecular characterization of a reassortant virus derived from Lassa and Mopeia viruses. Virus Genes 34(2):169\u2013176","journal-title":"Virus Genes"},{"issue":"1","key":"261_CR113","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41541-020-00219-x","volume":"5","author":"H M\u00fcller","year":"2020","unstructured":"M\u00fcller H, Fehling SK, Dorna J, Urbanowicz RA, Oestereich L, Krebs Y, Kolesnikova L, Schauflinger M, Kr\u00e4hling V, Magassouba N, Fichet-Calvet E, Ball JK, Kaufmann A, Bauer S, Becker S, von Messling V, Strecker T (2020) Adjuvant formulated virus-like particles expressing native-like forms of the Lassa virus envelope surface glycoprotein are immunogenic and induce antibodies with broadly neutralizing activity. NPJ Vaccines 5(1):71","journal-title":"NPJ Vaccines"},{"key":"261_CR114","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41541-017-0029-1","volume":"2","author":"VJ Munster","year":"2017","unstructured":"Munster VJ, Wells D, Lambe T, Wright D, Fischer RJ, Bushmaker T, Saturday G, van Doremalen N, Gilbert SC, de Wit E, Warimwe GM (2017) Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model. NPJ Vaccines 2:28","journal-title":"NPJ Vaccines"},{"issue":"2","key":"261_CR115","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1128\/JVI.01709-09","volume":"84","author":"MR Murawski","year":"2010","unstructured":"Murawski MR, McGinnes LW, Finberg RW, Kurt-Jones EA, Massare MJ, Smith G, Heaton PM, Fraire AE, Morrison TG (2010) Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB\/c mice, with no evidence of immunopathology. J Virol 84(2):1110\u20131123","journal-title":"J Virol"},{"issue":"10","key":"261_CR116","doi-asserted-by":"crossref","first-page":"4631","DOI":"10.1128\/AAC.00650-11","volume":"55","author":"BW Neuman","year":"2011","unstructured":"Neuman BW, Bederka LH, Stein DA, Ting JP, Moulton HM, Buchmeier MJ (2011) Development of peptide-conjugated morpholino oligomers as pan-arenavirus inhibitors. Antimicrob Agents Chemother 55(10):4631\u20134638","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"261_CR117","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2006-04-020263","volume":"108","author":"PP Ng","year":"2006","unstructured":"Ng PP, Helguera G, Daniels TR, Lomas SZ, Rodriguez JA, Schiller G, Bonavida B, Morrison SL, Penichet ML (2006) Molecular events contributing to cell death in malignant human hematopoietic cells elicited by an IgG3-avidin fusion protein targeting the transferrin receptor. Blood 108(8):2745\u20132754","journal-title":"Blood"},{"issue":"5","key":"261_CR118","doi-asserted-by":"crossref","first-page":"e0003793","DOI":"10.1371\/journal.pntd.0003793","volume":"9","author":"S Nikisins","year":"2015","unstructured":"Nikisins S, Rieger T, Patel P, M\u00fcller R, G\u00fcnther S, Niedrig M (2015) International external quality assessment study for molecular detection of Lassa virus. PLoS Negl Trop Dis 9(5):e0003793","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"261_CR119","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s12985-016-0621-4","volume":"13","author":"AE O\u2019Hearn","year":"2016","unstructured":"O\u2019Hearn AE, Voorhees MA, Fetterer DP, Wauquier N, Coomber MR, Bangura J, Fair JN, Gonzalez JP, Schoepp RJ (2016) Serosurveillance of viral pathogens circulating in West Africa. Virol J 13(1):163","journal-title":"Virol J"},{"issue":"6","key":"261_CR120","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1093\/infdis\/jiv522","volume":"213","author":"L Oestereich","year":"2016","unstructured":"Oestereich L, Rieger T, L\u00fcdtke A, Ruibal P, Wurr S, Pallasch E, Bockholt S, Krasemann S, Mu\u00f1oz-Fontela C, G\u00fcnther S (2016) Efficacy of Favipiravir alone and in combination with ribavirin in a lethal, immunocompetent mouse model of Lassa fever. J Infect Dis 213(6):934\u2013938","journal-title":"J Infect Dis"},{"issue":"6","key":"261_CR121","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1128\/JCM.02351-09","volume":"48","author":"S Olschl\u00e4ger","year":"2010","unstructured":"Olschl\u00e4ger S, Lelke M, Emmerich P, Panning M, Drosten C, Hass M, Asogun D, Ehichioya D, Omilabu S, G\u00fcnther S (2010) Improved detection of Lassa virus by reverse transcription-PCR targeting the 5\u2032 region of S RNA. J Clin Microbiol 48(6):2009\u20132013","journal-title":"J Clin Microbiol"},{"issue":"19","key":"261_CR122","doi-asserted-by":"crossref","first-page":"10516","DOI":"10.1128\/JVI.78.19.10516-10524.2004","volume":"78","author":"D Pannetier","year":"2004","unstructured":"Pannetier D, Faure C, Georges-Courbot MC, Deubel V, Baize S (2004) Human macrophages, but not dendritic cells, are activated and produce alpha\/beta interferons in response to Mopeia virus infection. J Virol 78(19):10516\u201310524","journal-title":"J Virol"},{"issue":"16","key":"261_CR123","doi-asserted-by":"crossref","first-page":"8293","DOI":"10.1128\/JVI.02120-10","volume":"85","author":"D Pannetier","year":"2011","unstructured":"Pannetier D, Reynard S, Russier M, Journeaux A, Tordo N, Deubel V, Baize S (2011) Human dendritic cells infected with the nonpathogenic Mopeia virus induce stronger T-cell responses than those infected with Lassa virus. J Virol 85(16):8293\u20138306","journal-title":"J Virol"},{"issue":"6","key":"261_CR124","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1128\/JVI.02077-15","volume":"90","author":"EI P\u00e9cheur","year":"2016","unstructured":"P\u00e9cheur EI, Borisevich V, Halfmann P, Morrey JD, Smee DF, Prichard M, Mire CE, Kawaoka Y, Geisbert TW, Polyak SJ (2016) The synthetic antiviral drug Arbidol inhibits globally prevalent pathogenic viruses. J Virol 90(6):3086\u20133092","journal-title":"J Virol"},{"issue":"22","key":"261_CR125","doi-asserted-by":"crossref","first-page":"12978","DOI":"10.1073\/pnas.2133782100","volume":"100","author":"M Perez","year":"2003","unstructured":"Perez M, Craven RC, de la Torre JC (2003) The small RING finger protein Z drives arenavirus budding: implications for antiviral strategies. Proc Natl Acad Sci USA 100(22):12978\u201312983","journal-title":"Proc Natl Acad Sci USA"},{"key":"261_CR126","doi-asserted-by":"crossref","first-page":"127983","DOI":"10.1016\/j.bmcl.2021.127983","volume":"41","author":"MB Plewe","year":"2021","unstructured":"Plewe MB, Gantla VR, Sokolova NV, Shin YJ, Naik S, Brown ER, Fetsko A, Zhang L, Kalveram B, Freiberg AN, Henkel G, McCormack K (2021) Discovery of a novel highly potent broad-spectrum heterocyclic chemical series of arenavirus cell entry inhibitors. Bioorg Med Chem Lett 41:127983","journal-title":"Bioorg Med Chem Lett"},{"key":"261_CR127","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.imlet.2019.03.008","volume":"215","author":"J Purushotham","year":"2019","unstructured":"Purushotham J, Lambe T, Gilbert SC (2019) Vaccine platforms for the prevention of Lassa fever. Immunol Lett 215:1\u201311","journal-title":"Immunol Lett"},{"issue":"23","key":"261_CR128","doi-asserted-by":"crossref","first-page":"11677","DOI":"10.1128\/JVI.75.23.11677-11685.2001","volume":"75","author":"P Pushko","year":"2001","unstructured":"Pushko P, Geisbert J, Parker M, Jahrling P, Smith J (2001) Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses. J Virol 75(23):11677\u201311685","journal-title":"J Virol"},{"issue":"30","key":"261_CR129","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1016\/j.vaccine.2010.04.093","volume":"28","author":"P Pushko","year":"2010","unstructured":"Pushko P, Kort T, Nathan M, Pearce MB, Smith G, Tumpey TM (2010) Recombinant H1N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus. Vaccine 28(30):4771\u20134776","journal-title":"Vaccine"},{"issue":"2","key":"261_CR130","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1006\/viro.1997.8878","volume":"239","author":"P Pushko","year":"1997","unstructured":"Pushko P, Parker M, Ludwig GV, Davis NL, Johnston RE, Smith JF (1997) Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 239(2):389\u2013401","journal-title":"Virology"},{"issue":"21","key":"261_CR131","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1016\/j.vaccine.2007.02.059","volume":"25","author":"P Pushko","year":"2007","unstructured":"Pushko P, Tumpey TM, Van Hoeven N, Belser JA, Robinson R, Nathan M, Smith G, Wright DC, Bright RA (2007) Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza. Vaccine 25(21):4283\u20134290","journal-title":"Vaccine"},{"issue":"6","key":"261_CR132","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1128\/JCM.00170-17","volume":"55","author":"V Raabe","year":"2017","unstructured":"Raabe V, Koehler J (2017) Laboratory diagnosis of Lassa fever. J Clin Microbiol 55(6):1629\u20131637","journal-title":"J Clin Microbiol"},{"issue":"5","key":"261_CR133","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/cid\/cix406","volume":"65","author":"VN Raabe","year":"2017","unstructured":"Raabe VN, Kann G, Ribner BS, Morales A, Varkey JB, Mehta AK, Lyon GM, Vanairsdale S, Faber K, Becker S, Eickmann M, Strecker T, Brown S, Patel K, De Leuw P, Schuettfort G, Stephan C, Rabenau H, Klena JD, Rollin PE, McElroy A, Str\u00f6her U, Nichol S, Kraft CS, Wolf T (2017) Favipiravir and ribavirin treatment of epidemiologically linked cases of Lassa fever. Clin Infect Dis 65(5):855\u2013859","journal-title":"Clin Infect Dis"},{"issue":"4","key":"261_CR134","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1414216","volume":"376","author":"JA Regules","year":"2017","unstructured":"Regules JA, Beigel JH, Paolino KM, Voell J, Castellano AR, Hu Z, Mu\u00f1oz P, Moon JE, Ruck RC, Bennett JW, Twomey PS, Guti\u00e9rrez RL, Remich SA, Hack HR, Wisniewski ML, Josleyn MD, Kwilas SA, Van Deusen N, Mbaya OT, Zhou Y, Stanley DA, Jing W, Smith KS, Shi M, Ledgerwood JE, Graham BS, Sullivan NJ, Jagodzinski LL, Peel SA, Alimonti JB, Hooper JW, Silvera PM, Martin BK, Monath TP, Ramsey WJ, Link CJ, Lane HC, Michael NL, Davey RT Jr, Thomas SJ (2017) A recombinant vesicular stomatitis virus Ebola vaccine. N Engl J Med 376(4):330\u2013341","journal-title":"N Engl J Med"},{"key":"261_CR135","doi-asserted-by":"crossref","first-page":"11544","DOI":"10.1038\/ncomms11544","volume":"7","author":"JE Robinson","year":"2016","unstructured":"Robinson JE, Hastie KM, Cross RW, Yenni RE, Elliott DH, Rouelle JA, Kannadka CB, Smira AA, Garry CE, Bradley BT, Yu H, Shaffer JG, Boisen ML, Hartnett JN, Zandonatti MA, Rowland MM, Heinrich ML, Mart\u00ednez-Sobrido L, Cheng B, de la Torre JC, Andersen KG, Goba A, Momoh M, Fullah M, Gbakie M, Kanneh L, Koroma VJ, Fonnie R, Jalloh SC, Kargbo B, Vandi MA, Gbetuwa M, Ikponmwosa O, Asogun DA, Okokhere PO, Follarin OA, Schieffelin JS, Pitts KR, Geisbert JB, Kulakoski PC, Wilson RB, Happi CT, Sabeti PC, Gevao SM, Khan SH, Grant DS, Geisbert TW, Saphire EO, Branco LM, Garry RF (2016) Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits. Nat Commun 7:11544","journal-title":"Nat Commun"},{"issue":"9","key":"261_CR136","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.3201\/eid2409.180233","volume":"24","author":"K Rosenke","year":"2018","unstructured":"Rosenke K, Feldmann H, Westover JB, Hanley PW, Martellaro C, Feldmann F, Saturday G, Lovaglio J, Scott DP, Furuta Y, Komeno T, Gowen BB, Safronetz D (2018) Use of Favipiravir to treat Lassa virus infection in macaques. Emerg Infect Dis 24(9):1696\u20131699","journal-title":"Emerg Infect Dis"},{"issue":"4","key":"261_CR137","doi-asserted-by":"crossref","first-page":"e0003736","DOI":"10.1371\/journal.pntd.0003736","volume":"9","author":"D Safronetz","year":"2015","unstructured":"Safronetz D, Mire C, Rosenke K, Feldmann F, Haddock E, Geisbert T, Feldmann H (2015a) A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses. PLoS Negl Trop Dis 9(4):e0003736","journal-title":"PLoS Negl Trop Dis"},{"key":"261_CR138","doi-asserted-by":"crossref","first-page":"14775","DOI":"10.1038\/srep14775","volume":"5","author":"D Safronetz","year":"2015","unstructured":"Safronetz D, Rosenke K, Westover JB, Martellaro C, Okumura A, Furuta Y, Geisbert J, Saturday G, Komeno T, Geisbert TW, Feldmann H, Gowen BB (2015b) The broad-spectrum antiviral Favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset. Sci Rep 5:14775","journal-title":"Sci Rep"},{"key":"261_CR139","doi-asserted-by":"crossref","unstructured":"Sahin M, Remy MM, Merkler D, Pinschewer DD (2021) The Janus Kinase inhibitor ruxolitinib prevents terminal shock in a mouse model of arenavirus hemorrhagic fever. Microorganisms 9(3)","DOI":"10.3390\/microorganisms9030564"},{"key":"261_CR140","doi-asserted-by":"crossref","unstructured":"Salvato MS, Domi A, Guzm\u00e1n-Cardozo C, Medina-Moreno S, Zapata JC, Hsu H, McCurley N, Basu R, Hauser M, Hellerstein M, Guirakhoo F (2019) A single dose of modified vaccinia ankara expressing lassa virus-like particles protects mice from lethal intra-cerebral virus challenge. Pathogens 8(3)","DOI":"10.3390\/pathogens8030133"},{"issue":"Pt 5","key":"261_CR141","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1099\/0022-1317-70-5-1125","volume":"70","author":"A Sanchez","year":"1989","unstructured":"Sanchez A, Pifat DY, Kenyon RH, Peters CJ, McCormick JB, Kiley MP (1989) Junin virus monoclonal antibodies: characterization and cross-reactivity with other arenaviruses. J Gen Virol 70(Pt 5):1125\u20131132","journal-title":"J Gen Virol"},{"issue":"1","key":"261_CR142","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1128\/JCM.01693-16","volume":"55","author":"NG Satterly","year":"2017","unstructured":"Satterly NG, Voorhees MA, Ames AD, Schoepp RJ (2017) Comparison of MagPix assays and enzyme-linked immunosorbent assay for detection of hemorrhagic fever viruses. J Clin Microbiol 55(1):68\u201378","journal-title":"J Clin Microbiol"},{"key":"261_CR143","doi-asserted-by":"crossref","first-page":"107512","DOI":"10.1016\/j.pharmthera.2020.107512","volume":"209","author":"K Shiraki","year":"2020","unstructured":"Shiraki K, Daikoku T (2020) Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol Ther 209:107512","journal-title":"Pharmacol Ther"},{"issue":"15","key":"261_CR144","doi-asserted-by":"crossref","first-page":"8556","DOI":"10.1128\/JVI.01133-14","volume":"88","author":"JS Spence","year":"2014","unstructured":"Spence JS, Melnik LI, Badani H, Wimley WC, Garry RF (2014) Inhibition of arenavirus infection by a glycoprotein-derived peptide with a novel mechanism. J Virol 88(15):8556\u20138564","journal-title":"J Virol"},{"key":"261_CR145","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/1743-422X-7-146","volume":"7","author":"G Spohn","year":"2010","unstructured":"Spohn G, Jennings GT, Martina BE, Keller I, Beck M, Pumpens P, Osterhaus AD, Bachmann MF (2010) A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice. Virol J 7:146","journal-title":"Virol J"},{"issue":"1","key":"261_CR146","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2353\/jmoldx.2010.090035","volume":"12","author":"R Stadhouders","year":"2010","unstructured":"Stadhouders R, Pas SD, Anber J, Voermans J, Mes TH, Schutten M (2010) The effect of primer-template mismatches on the detection and quantification of nucleic acids using the 5\u2019 nuclease assay. J Mol Diagn 12(1):109\u2013117","journal-title":"J Mol Diagn"},{"key":"261_CR147","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41541-019-0104-x","volume":"4","author":"DR Stein","year":"2019","unstructured":"Stein DR, Warner BM, Soule G, Tierney K, Frost KL, Booth S, Safronetz D (2019) A recombinant vesicular stomatitis-based Lassa fever vaccine elicits rapid and long-term protection from lethal Lassa virus infection in guinea pigs. NPJ Vaccines 4:8","journal-title":"NPJ Vaccines"},{"key":"261_CR148","doi-asserted-by":"crossref","unstructured":"Stylianou E, Harrington-Kandt R, Beglov J, Bull N, Pinpathomrat N, Swarbrick GM, Lewinsohn DA, Lewinsohn DM, McShane H (2018) Identification and evaluation of novel protective antigens for the development of a candidate tuberculosis subunit vaccine. Infect Immun 86(7)","DOI":"10.1128\/IAI.00014-18"},{"issue":"23","key":"261_CR149","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1016\/j.vaccine.2004.11.070","volume":"23","author":"DL Swenson","year":"2005","unstructured":"Swenson DL, Warfield KL, Negley DL, Schmaljohn A, Aman MJ, Bavari S (2005) Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. Vaccine 23(23):3033\u20133042","journal-title":"Vaccine"},{"issue":"39","key":"261_CR150","doi-asserted-by":"crossref","first-page":"4998","DOI":"10.1016\/j.vaccine.2008.07.011","volume":"26","author":"JM Thompson","year":"2008","unstructured":"Thompson JM, Whitmore AC, Staats HF, Johnston R (2008) The contribution of type I interferon signaling to immunity induced by alphavirus replicon vaccines. Vaccine 26(39):4998\u20135003","journal-title":"Vaccine"},{"key":"261_CR151","doi-asserted-by":"crossref","unstructured":"Torriani G, Trofimenko E, Mayor J, Fedeli C, Moreno H, Michel S, Heulot M, Chevalier N, Zimmer G, Shrestha N, Plattet P, Engler O, Rothenberger S, Widmann C, Kunz S (2019) Identification of clotrimazole derivatives as specific inhibitors of arenavirus fusion. J Virol 93(6)","DOI":"10.1128\/JVI.01744-18"},{"issue":"5","key":"261_CR152","doi-asserted-by":"crossref","first-page":"954","DOI":"10.4269\/ajtmh.2010.09-0636","volume":"82","author":"AR Trombley","year":"2010","unstructured":"Trombley AR, Wachter L, Garrison J, Buckley-Beason VA, Jahrling J, Hensley LE, Schoepp RJ, Norwood DA, Goba A, Fair JN, Kulesh DA (2010) Comprehensive panel of real-time TaqMan polymerase chain reaction assays for detection and absolute quantification of filoviruses, arenaviruses, and New World hantaviruses. Am J Trop Med Hyg 82(5):954\u2013960","journal-title":"Am J Trop Med Hyg"},{"issue":"11","key":"261_CR153","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1128\/AAC.46.11.3613-3616.2002","volume":"46","author":"FM Uckun","year":"2002","unstructured":"Uckun FM, Pendergrass S, Venkatachalam TK, Qazi S, Richman D (2002) Stampidine is a potent inhibitor of Zidovudine- and nucleoside analog reverse transcriptase inhibitor-resistant primary clinical human immunodeficiency virus type 1 isolates with thymidine analog mutations. Antimicrob Agents Chemother 46(11):3613\u20133616","journal-title":"Antimicrob Agents Chemother"},{"key":"261_CR154","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2334-4-1","volume":"4","author":"FM Uckun","year":"2004","unstructured":"Uckun FM, Petkevich AS, Vassilev AO, Tibbles HE, Titov L (2004) Stampidine prevents mortality in an experimental mouse model of viral hemorrhagic fever caused by lassa virus. BMC Infect Dis 4:1","journal-title":"BMC Infect Dis"},{"issue":"1","key":"261_CR155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1466252312000011","volume":"13","author":"RL Vander Veen","year":"2012","unstructured":"Vander Veen RL, Harris DL, Kamrud KI (2012) Alphavirus replicon vaccines. Anim Health Res Rev 13(1):1\u20139","journal-title":"Anim Health Res Rev"},{"issue":"Suppl 2","key":"261_CR156","doi-asserted-by":"crossref","first-page":"S430","DOI":"10.1086\/520583","volume":"196","author":"KL Warfield","year":"2007","unstructured":"Warfield KL, Swenson DL, Olinger GG, Kalina WV, Aman MJ, Bavari S (2007) Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis 196(Suppl 2):S430-437","journal-title":"J Infect Dis"},{"key":"261_CR157","doi-asserted-by":"crossref","unstructured":"Warimwe GM, Gesharisha J, Carr BV, Otieno S, Otingah K, Wright D, Charleston B, Okoth E, Elena LG, Lorenzo G, Ayman EB, Alharbi NK, Al-dubaib MA, Brun A, Gilbert SC, Nene V, Hill AV (2016) Chimpanzee adenovirus vaccine provides multispecies protection against rift valley fever. Sci Rep 6:20617","DOI":"10.1038\/srep20617"},{"key":"261_CR158","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.2147\/DDDT.S147276","volume":"12","author":"BM Warner","year":"2018","unstructured":"Warner BM, Safronetz D, Stein DR (2018) Current research for a vaccine against Lassa hemorrhagic fever virus. Drug Des Devel Ther 12:2519\u20132527","journal-title":"Drug Des Devel Ther"},{"issue":"7496","key":"261_CR159","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature13027","volume":"508","author":"TK Warren","year":"2014","unstructured":"Warren TK, Wells J, Panchal RG, Stuthman KS, Garza NL, Van Tongeren SA, Dong L, Retterer CJ, Eaton BP, Pegoraro G, Honnold S, Bantia S, Kotian P, Chen X, Taubenheim BR, Welch LS, Minning DM, Babu YS, Sheridan WP, Bavari S (2014) Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 508(7496):402\u2013405","journal-title":"Nature"},{"issue":"11","key":"261_CR160","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1021\/jm00281a014","volume":"15","author":"JT Witkowski","year":"1972","unstructured":"Witkowski JT, Robins RK, Sidwell RW, Simon LN (1972) Design, synthesis, and broad spectrum antiviral activity of 1-D-ribofuranosyl-1,2,4-triazole-3-carboxamide and related nucleosides. J Med Chem 15(11):1150\u20131154","journal-title":"J Med Chem"},{"issue":"5","key":"261_CR161","doi-asserted-by":"crossref","first-page":"e0010433","DOI":"10.1371\/journal.pntd.0010433","volume":"16","author":"C Woolsey","year":"2022","unstructured":"Woolsey C, Cross RW, Agans KN, Borisevich V, Deer DJ, Geisbert JB, Gerardi C, Latham TE, Fenton KA, Egan MA, Eldridge JH, Geisbert TW, Matassov D (2022) A highly attenuated Vesiculovax vaccine rapidly protects nonhuman primates against lethal Marburg virus challenge. PLoS Negl Trop Dis 16(5):e0010433","journal-title":"PLoS Negl Trop Dis"},{"issue":"4895","key":"261_CR162","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1126\/science.2922607","volume":"243","author":"C Xiong","year":"1989","unstructured":"Xiong C, Levis R, Shen P, Schlesinger S, Rice CM, Huang HV (1989) Sindbis virus: an efficient, broad host range vector for gene expression in animal cells. Science 243(4895):1188\u20131191","journal-title":"Science"},{"key":"261_CR163","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1743-422X-10-52","volume":"10","author":"JC Zapata","year":"2013","unstructured":"Zapata JC, Poonia B, Bryant J, Davis H, Ateh E, George L, Crasta O, Zhang Y, Slezak T, Jaing C, Pauza CD, Goicochea M, Moshkoff D, Lukashevich IS, Salvato MS (2013) An attenuated Lassa vaccine in SIV-infected rhesus macaques does not persist or cause arenavirus disease but does elicit Lassa virus-specific immunity. Virol J 10:52","journal-title":"Virol J"},{"key":"261_CR164","doi-asserted-by":"crossref","unstructured":"Zeitlin L, Cross RW, Geisbert JB, Borisevich V, Agans KN, Prasad AN, Enterlein S, Aman MJ, Bornholdt ZA, Brennan MB, Campbell L, Kim D, Mlakar N, Moyer CL, Pauly MH, Shestowsky W, Whaley KJ, Fenton KA, Geisbert TW (2021) Therapy for argentine hemorrhagic fever in nonhuman primates with a humanized monoclonal antibody. Proc Natl Acad Sci USA 118(11)","DOI":"10.1073\/pnas.2023332118"},{"issue":"16","key":"261_CR165","doi-asserted-by":"crossref","first-page":"4458","DOI":"10.1073\/pnas.1600996113","volume":"113","author":"L Zeitlin","year":"2016","unstructured":"Zeitlin L, Geisbert JB, Deer DJ, Fenton KA, Bohorov O, Bohorova N, Goodman C, Kim D, Hiatt A, Pauly MH, Velasco J, Whaley KJ, Altmann F, Gruber C, Steinkellner H, Honko AN, Kuehne AI, Aman MJ, Sahandi S, Enterlein S, Zhan X, Enria D, Geisbert TW (2016) Monoclonal antibody therapy for Junin virus infection. Proc Natl Acad Sci USA 113(16):4458\u20134463","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Current Topics in Microbiology and Immunology","Lassa Fever: Epidemiology, Immunology, Diagnostics, and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/82_2022_261","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T08:07:44Z","timestamp":1689581264000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/82_2022_261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"ISBN":["9783031358067","9783031358074"],"references-count":165,"URL":"https:\/\/doi.org\/10.1007\/82_2022_261","relation":{},"ISSN":["0070-217X","2196-9965"],"issn-type":[{"value":"0070-217X","type":"print"},{"value":"2196-9965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"18 October 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}